Showing 1765 results
-
Press release /If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP…
-
Press release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Press release /After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
-
Press release /Ce candidat-médicament pourrait s'avérer déterminant dans la lutte contre le paludisme en éliminant rapidement l'infection paludéenne, y compris les souches résistantes et en bloquant la…
-
Press release /Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of…
-
Story /A conversation with Novartis Chief Digital Officer Bertrand Bodson
-
Press release /Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
-
Press release /New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and demonstrated…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III…